Dr. Nir Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine, he is a professor in the departments of Medicine and Genetics, the director of the Institute for Aging Research, and the director of the Einstein-National Institutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, and the author of >330 papers.
He made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Dr. Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging.
Dr. Barzilai is a co-founder and the President of AHLS. He is also on the American Federation for Aging Research board of directors, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the council of the Healthy Longevity Medicine Society.
He authored Age Later: Health Span, Life Span, and the New Science of Longevity.